Moscow, December 25, 2024 – The Europe Today: Russian scientists are nearing the completion of a revolutionary cancer vaccine, slated for release in September 2025, according to Alexander Gintsburg, head of the Gamaleya Research Institute of Epidemiology and Microbiology.
The Gamaleya Center, known for developing the Sputnik V Covid-19 vaccine in 2020, has leveraged advancements in mRNA technology to create a therapeutic vaccine aimed at treating cancer patients. This innovative drug works by activating the immune system to identify and destroy malignant cells.
“This vaccine enables cytotoxic lymphocytes (white blood cells) to recognize foreign proteins on tumor cells, destroying them throughout the body,” Gintsburg explained. The approach allows for the production of high concentrations of target proteins, enhancing the immune response to cancer.
The vaccine is a personalized treatment, as each patient’s drug will be tailored to their unique tumor profile. Researchers have demonstrated its effectiveness in animal models, particularly against melanoma. Efforts are now underway to develop models for non-small-cell lung cancer, pancreatic cancer, and certain kidney cancers, which are among the most challenging to treat with existing methods.
By September 2025, clinical trials will begin at the Hertsen Oncological Research Institute and the Blokhin Cancer Center, targeting a limited group of patients. Following registration by the Ministry of Health, the treatment is expected to expand to other medical facilities across Russia.
This breakthrough represents a major stride in oncology, offering hope for more effective and personalized cancer treatments.
